Open AccessEfficacy and safety of the compound Chinese medicine SaiLuoTong in vascular dementia: A randomized clinical trial
Author(s) -
Jia Jianping,
Wei Cuibai,
Chen Shuoqi,
Li Fangyu,
Tang Yi,
Qin Wei,
Shi Lu,
Gong Min,
Xu Hui,
Li Fang,
He Jia,
Song Haiqing,
Yang Shanshan,
Zhou Aihong,
Wang Fen,
Zuo Xiumei,
Chu Changbiao,
Liang Junhua,
Jia Longfei,
Gauthier Serge
Publication year - 2018
Publication title -
alzheimer's and dementia: translational research and clinical interventions
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.49
H-Index - 30
ISSN - 2352-8737
DOI - 10.1016/j.trci.2018.02.004
Subject(s) - medicine , placebo , vascular dementia , placebo group , dementia , randomized controlled trial , confidence interval , significant difference , clinical trial , alternative medicine , pathology , disease
No licensed medications are available to treat vascular dementia (VaD). Methods Patients were randomly assigned to experimental groups (SaiLuoTong [SLT] 360 or 240 mg for groups A and B for 52 weeks, respectively) or placebo group (SLT 360 mg and 240 mg for group C only from weeks 27 to 52, respectively). Results Three hundred twenty‐five patients were included in final analysis. At week 26, the difference in VaD Assessment Scale–cognitive subscale scores was 2.67 (95% confidence interval, 1.54 to 3.81) for groups A versus C, and 2.48 (1.34 to 3.62) for groups B versus C (both P < .0001). However, at week 52, no difference was observed among the groups on the VaD Assessment Scale–cognitive subscale ( P = .062) because of the emerging efficacy of SLT in placebo beginning at week 27. Discussion This study suggests that SLT is effective for treatment of VaD, and this compound Chinese medicine may represent a better choice to treat VaD.